Morgan Stanley analyst Terence Flynn raised the firm’s price target on Royalty Pharma (RPRX) to $63 from $61 and keeps an Overweight rating on the shares. The firm adjusted models among its biopharma coverage for IQVIA trends as well as intra-quarter updates ahead of Q1 earnings reporting from the group.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RPRX:
- Royalty Pharma reports co-funding agreement with Johnson & Johnson for JNJ-4804
- Zymeworks price target raised to $48 from $33 at Evercore ISI
- Royalty Pharma appoints Kenneth Sun as Senior Vice President, Head of Asia
- Zymeworks, Royalty Pharma enter $250M royalty-backed note financing
- Royalty Pharma price target raised to $50 from $45 at TD Cowen